NCT03578952 (Pure AR TAVR) is a NA clinical trial of TAVR with Evolut R valve in Aortic Valve, sponsored by Seung-Jung Park.

Who is sponsoring NCT03578952?

NCT03578952 is sponsored by Seung-Jung Park.

What drugs are being tested in NCT03578952?

Interventions in NCT03578952: TAVR with Evolut R valve.

What condition does NCT03578952 study?

NCT03578952 studies Aortic Valve, Aortic Valve Insufficiency, Aortic Regurgitation, Regurgitation, Aortic Valve, Aortic Incompetence.

Is NCT03578952 still recruiting?

NCT03578952 is currently terminated. Last updated 22 February 2019.

Last reviewed 2019-02-22 · How we verify

NCT03578952: Pure AR TAVR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Effectiveness and Safety of Evolut R Valve In Patients With Pure Aortic Regurgitation

Terminated NA Last updated 22 February 2019

What this trial tests

NA trial testing TAVR with Evolut R valve in Aortic Valve in 2 participants. Terminated before completion.

Timeline

10 August 2018

Primary endpoint
21 February 2019

21 February 2019

Quick facts

Lead sponsor	Seung-Jung Park
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	10 August 2018
Primary completion	21 February 2019
Estimated completion	21 February 2019
Sites	1 location across South Korea

Drugs / interventions tested

TAVR with Evolut R valve

Conditions studied

Aortic Valve — all drugs for Aortic Valve →
Aortic Valve Insufficiency — all drugs for Aortic Valve Insufficiency →
Aortic Regurgitation — all drugs for Aortic Regurgitation →
Regurgitation, Aortic Valve — all drugs for Regurgitation, Aortic Valve →

Sponsor

Seung-Jung Park — full company profile →

Who can join

20 and older, any sex, with Aortic Valve or Aortic Valve Insufficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to evaluate the efficacy and safety of transcatheter aortic valve replacement (TAVR) in severe 'pure Aortic regurgitation (AR)' using Evolut R valve (Medtronic, Minneapolis, MN).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Seung-Jung Park trials

Trials by the same sponsor.

NCT06908499 — The DECISION-CTO Extended 10 Y Follow-up · not yet recruiting
NCT06177743 — IRIS-Coroflex NEO Cohort · recruiting
NCT05125367 — Ten-Year Outcomes of Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation i · completed
NCT03967158 — Evaluation of Effectiveness and Safety of XIENCE Sierra in Routine Clinical Practice · active not recruiting
NCT03190057 — IRIS-BioFreedom Cohort in the IRIS-DES Registry · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03578952 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seung-Jung Park
Last refreshed: 22 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03578952.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing